Bioluminescence enters biotech venture spotlight with almost $500M under management mbayer Tue, 10/31/2023 - 16:17.: Bioluminescence is rocketing out of stealth, looking to warm a frigid funding environment with the embrace of fresh funding. The new venture capital outfit is entering the fold with $477 million in assets under management across two funds, including investments in startups like genetic-medicines-focused ReCode Therapeutics and neuroscience biotech Nido Biosciences, according to Wednesday’s unveiling. The two funds are Bioluminescence Ventures Fund I and II, respectively. “Innovation never stops, even when financing does,” Founding and Managing Partner Kouki Harasaki, Ph.D., said in a release.